| Figure 1‑1: Orthopedic Biomaterials Market Share Ranking by Segment, U.S., 2023 (1 of 2) |
| Figure 1‑2: Orthopedic Biomaterials Market Share Ranking by Segment, U.S., 2023 (2 of 2) |
| Figure 1‑3: Companies Researched in This Report |
| Figure 1‑4: Factors Impacting the Orthopedic Biomaterials Market by Segment, U.S. (1 of 2) |
| Figure 1‑5: Factors Impacting the Orthopedic Biomaterials Market by Segment, U.S. (2 of 2) |
| Figure 1‑6: Recent Events in the Orthopedic Biomaterials Market, U.S., 2021 – 2024 (1 of 6) |
| Figure 1‑7: Recent Events in the Orthopedic Biomaterials Market, U.S., 2021 – 2024 (2 of 6) |
| Figure 1‑8: Recent Events in the Orthopedic Biomaterials Market, U.S., 2021 – 2024 (3 of 6) |
| Figure 1‑9: Recent Events in the Orthopedic Biomaterials Market, U.S., 2021 – 2024 (4 of 6) |
| Figure 1‑10: Recent Events in the Orthopedic Biomaterials Market, U.S., 2021 – 2024 (5 of 6) |
| Figure 1‑11: Recent Events in the Orthopedic Biomaterials Market, U.S., 2021 – 2024 (6 of 6) |
| Figure 1‑12: Orthopedic Biomaterials Procedures Covered (1 of 4) |
| Figure 1‑13: Orthopedic Biomaterials Procedures Covered (2 of 4) |
| Figure 1‑14: Orthopedic Biomaterials Procedures Covered (3 of 4) |
| Figure 1‑15: Orthopedic Biomaterials Procedures Covered (4 of 4) |
| Figure 1‑16: Procedure Codes Investigated |
| Figure 1‑17: Orthopedic Biomaterials Markets Covered (1 of 6) |
| Figure 1‑18: Orthopedic Biomaterials Markets Covered (2 of 6) |
| Figure 1‑19: Orthopedic Biomaterials Markets Covered (3 of 6) |
| Figure 1‑20: Orthopedic Biomaterials Markets Covered (4 of 6) |
| Figure 1‑21: Orthopedic Biomaterials Markets Covered (5 of 6) |
| Figure 1‑22: Orthopedic Biomaterials Markets Covered (6 of 6) |
| Figure 1‑23: Key Report Updates |
| Figure 1‑24: Version History |
| Figure 2‑1: Orthopedic Biomaterials Market by Segment, Worst Case Scenario, U.S., 2020 – 2030 (US$M) |
| Figure 2‑2: Orthopedic Biomaterials Market by Segment, Base Case Scenario, U.S., 2020 – 2030 (US$M) |
| Figure 2‑3: Orthopedic Biomaterials Market by Segment, Best Case Scenario, U.S., 2020 – 2030 (US$M) |
| Figure 4‑1: Bone Graft Substitutes Products by Company (1 of 4) |
| Figure 4‑2: Bone Graft Substitutes Products by Company (2 of 4) |
| Figure 4‑3: Bone Graft Substitutes Products by Company (3 of 4) |
| Figure 4‑4: Bone Graft Substitutes Products by Company (4 of 4) |
| Figure 4‑5: Growth Factor Products by Company |
| Figure 4‑6: Cellular Allograft Products by Company |
| Figure 4‑7: Cell Therapy Products by Company |
| Figure 4‑8: Hyaluronic Acid Viscosupplementation by Products by Company |
| Figure 4‑9: Cartilage Repair Products by Company |
| Figure 4‑10: Class 2 Device Recall GRAFTON DBM (Gel, Flex, Putty, Matrix, Crunch) |
| Figure 4‑11: Class 2 Device Recall GRAFTON PLUS DBM Paste |
| Figure 4‑12: Class 2 Device Recall Magnifuse Bone Graft |
| Figure 4‑13: Class 2 Device Recall Grafton DBF Inject |
| Figure 4‑14: Class 2 Device Recall OsteoSelect Demineralized Bone Matrix (DBM) Putty |
| Figure 4‑15: Class 2 Device Recall PROSTIM 10cc INJECTABLE |
| Figure 4‑16: Class 2 Device Recall Opteform Allograft Disc |
| Figure 4‑17: Class 2 Device Recall Bioactive Bone Graft Putty |
| Figure 4‑18: Class 3 Device Recall iFACTOR Peptide Enhanced Bone Graft Putty |
| Figure 4‑19: ACDF Using Structural Allograft vs. Tritanium C |
| Figure 4‑20: Clinical Study of Bone Graft Substitutes in Orthopaedic and Spinal Applications |
| Figure 4‑21: OSTEOAMP Lumbar Fusion Intra-Patient Controlled Study |
| Figure 4‑22: Rate of Bony Fusion Using NanoBone® Synthetic Bone Graft Versus Local Autologous Bone Graft. (BONE) |
| Figure 4‑23: Demineralized Bone Matrix Rotator Cuff Study |
| Figure 4‑24: Clinical Outcomes Associated with the Use of ViviGen® for the Treatment of Lumbar Degenerative Disc Disease |
| Figure 4‑25: The Effect of Bone-void Filler on Anterior Knee Pain Following ACL Reconstruction |
| Figure 4‑26: Long-term Safety and Effectiveness of AUGMENT® Injectable Bone Graft Compared to Autologous Bone Graft |
| Figure 4‑27: Transforaminal Lumbar Interbody Fusion (TLIF) |
| Figure 4‑28: A Post Market Surveillance on INFUSE Bone Graft |
| Figure 4‑29: Long-term Safety and Effectiveness of AUGMENT® Injectable Bone Graft Compared to Autologous Bone Graft |
| Figure 4‑30: Evaluation of the Effectiveness of AMPLEX® Compared to Autogenous Bone Grafts |
| Figure 4‑31: Safety, Efficacy, & Use of ViviGen Cellular Bone Matrix Allograft in Orthopaedic Fracture Care |
| Figure 4‑32: MagnetOs Putty Compared to Trinity Evolution in Patients Undergoing up to Four-level Instrumented Posterolateral Fusion |
| Figure 4‑33: Clinical Outcomes Associated with the Use of ViviGen® for the Treatment of Lumbar Degenerative Disc Disease (ViviGen) |
| Figure 4‑34: Trinity Elite in Lumbar Fusion |
| Figure 4‑35: An ACDF Multi-Center Study Using ViviGen Cellular Bone Matrix |
| Figure 4‑36: ViviGen Cellular Bone Matrix for Hindfoot or Ankle Arthrodesis (ViviGen) |
| Figure 4‑37: Effect of PRP, PPP, & BMAC on Functional Outcomes Following Hip Arthroscopy for Acetabular Labral Pathologies |
| Figure 4‑38: Bone Marrow Aspirate Concentrate (BMAC) vs Corticosteroid Injection |
| Figure 4‑39: BMAC & Allograft vs BMP-2 |
| Figure 4‑40: Bone Marrow Aspirate Concentrate (BMAC)Treatment for Knee Osteoarthritis (BMAC) |
| Figure 4‑41: Platelet Rich Plasma in Knee Osteoarthritis |
| Figure 4‑42: Platelet-Rich Plasma (PRP) for Treatment of Symptomatic Lumbar Facet Syndrome of the Spine |
| Figure 4‑43: A Prospective Study of Clinical Outcomes Following a Single Intradiscal Injection of Bone Marrow Aspirate Concentrate (BMAC) for Single Level Discogenic Low Back Pain |
| Figure 4‑44: ArtiAid® for Knee Osteoarthritis: A Post-market Study |
| Figure 4‑45: The Effectiveness of Different Doses of Hyaluronic Acid Injections in Knee Osteoarthritis |
| Figure 4‑46: Euflexxa for the Treatment of Osteoarthritis |
| Figure 4‑47: MONOVISC for Ankle Joint Pain Relief |
| Figure 4‑48: MONOVISC for Shoulder Joint Pain Relief |
| Figure 4‑49: MONOVISC for Hip Joint Pain Relief |
| Figure 4‑50: Comparison of Hyaluronic Acid and Platelet-Rich Plasma Injections |
| Figure 4‑51: Prospective Evaluation of ProChondrix CR for Repair of Articular Cartilage Defects on Femoral Condyle and Patella |
| Figure 4‑52: Osteochondral Allograft in the Surgical Treatment of Basal Joint Arthritis |
| Figure 4‑53: Phase 2 Clinical Trial of CartiLife® in the United States |
| Figure 4‑54: A Study to Evaluate the Efficacy of BioCartilage® Micronized Cartilage Matrix in Microfracture Treatment of Osteochondral Defects |
| Figure 5‑1: Orthopedic Biomaterials Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 5‑2: Leading Competitors, Orthopedic Biomaterials Market, U.S., 2023 (1 of 2) |
| Figure 5‑3: Leading Competitors, Orthopedic Biomaterials Market, U.S., 2023 (2 of 2) |
| Figure 5‑4: SWOT Analysis, Arthrex |
| Figure 5‑5: SWOT Analysis, Biocomposites |
| Figure 5‑6: SWOT Analysis, Bioventus |
| Figure 5‑7: SWOT Analysis, DePuy Synthes |
| Figure 5‑8: SWOT Analysis, Ferring Pharmaceuticals |
| Figure 5‑9: SWOT Analysis, Isto Biologics |
| Figure 5‑10: SWOT Analysis, Medtronic |
| Figure 5‑11: SWOT Analysis, MTF |
| Figure 5‑12: SWOT Analysis, NuVasive |
| Figure 5‑13: SWOT Analysis, Orthofix |
| Figure 5‑14: SWOT Analysis, Sanofi |
| Figure 5‑15: SWOT Analysis, Stryker |
| Figure 5‑16: SWOT Analysis, Terumo |
| Figure 5‑17: SWOT Analysis, Vericel |
| Figure 5‑18: SWOT Analysis, Zimmer Biomet |
| Figure 6‑1: Procedure Codes Investigated, U.S., 2023 |
| Figure 6‑2: Orthopedic Biomaterials Procedures by Segment, U.S., 2020 – 2030 |
| Figure 6‑3: Orthopedic Bone Grafting Procedures by Material, U.S., 2020 – 2030 |
| Figure 6‑4: Orthopedic Bone Grafting Procedures by Indication, U.S., 2020 – 2030 (1 of 2) |
| Figure 6‑5: Orthopedic Bone Grafting Procedures by Indication, U.S., 2020 – 2030 (2 of 2) |
| Figure 6‑6: Average Units Used per Procedure by Indication, U.S., 2020 – 2030 |
| Figure 6‑7: Autograft Procedures by Indication, U.S., 2020 – 2030 (1 of 2) |
| Figure 6‑8: Autograft Procedures by Indication, U.S., 2020 – 2030 (2 of 2) |
| Figure 6‑9: Allograft Procedures by Indication, U.S., 2020 – 2030 (1 of 2) |
| Figure 6‑10: Allograft Procedures by Indication, U.S., 2020 – 2030 (2 of 2) |
| Figure 6‑11: Xenograft Procedures by Indication, U.S., 2020 – 2030 (1 of 2) |
| Figure 6‑12: Xenograft Procedures by Indication, U.S., 2020 – 2030 (2 of 2) |
| Figure 6‑13: DBM Procedures by Indication, U.S., 2020 – 2030 (1 of 2) |
| Figure 6‑14: DBM Procedures by Indication, U.S., 2020 – 2030 (2 of 2) |
| Figure 6‑15: Synthetic Procedures by Indication, U.S., 2020 – 2030 (1 of 2) |
| Figure 6‑16: Synthetic Procedures by Indication, U.S., 2020 – 2030 (2 of 2) |
| Figure 6‑17: Allograft Procedures by Patient Type, U.S., 2020-2030 |
| Figure 6‑18: Xenograft Procedures by Patient Type, U.S., 2020-2030 |
| Figure 6‑19: DBM Procedures by Patient Type, U.S., 2020-2030 |
| Figure 6‑20: Synthetic Procedures by Patient Type, U.S., 2020-2030 |
| Figure 6‑21: Orthopedic Bone Grafting Procedures by Care Setting, U.S., 2020-2030 |
| Figure 6‑22: Orthopedic Growth Factor Procedures by Indication, U.S., 2020 – 2030 |
| Figure 6‑23: Orthopedic Growth Factor Procedures by Care Setting, U.S., 2020 – 2030 |
| Figure 6‑24: Cellular Allograft Procedures by Anatomy, U.S., 2020 – 2030 |
| Figure 6‑25: Cellular Allograft Procedures by Patient Type, U.S., 2020 – 2030 |
| Figure 6‑26: Cellular Allograft Procedures by Care Setting, U.S., 2020 – 2030 |
| Figure 6‑27: Orthopedic Cell Therapy Procedures by Material Type, U.S., 2020 – 2030 |
| Figure 6‑28: Platelet-Rich Plasma Procedures by Indication, U.S., 2020 – 2030 (1 of 2) |
| Figure 6‑29: Platelet-Rich Plasma Procedures by Indication, U.S., 2020 – 2030 (2 of 2) |
| Figure 6‑30: Bone Marrow Aspirate Concentrate Procedures by Indication, U.S., 2020 – 2030 (1 of 2) |
| Figure 6‑31: Bone Marrow Aspirate Concentrate Procedures by Indication, U.S., 2020 – 2030 (2 of 2) |
| Figure 6‑32: Orthopedic Cell Therapy Procedures by Patient Type, U.S., 2020 – 2030 |
| Figure 6‑33: Orthopedic Cell Therapy Procedures by Care Setting, U.S., 2020 – 2030 |
| Figure 6‑34: Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle, U.S., 2020 – 2030 (1 of 2) |
| Figure 6‑35: Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle, U.S., 2020 – 2030 (2 of 2) |
| Figure 6‑36: Hyaluronic Acid Viscosupplementation Procedures by Patient Type, U.S., 2020 – 2030 |
| Figure 6‑37: Hyaluronic Acid Viscosupplementation Procedures by Care Setting, U.S., 2020 – 2030 |
| Figure 6‑38: Orthopedic Cartilage Repair Procedures by Type, U.S., 2020 – 2030 (1 of 2) |
| Figure 6‑39: Orthopedic Cartilage Repair Procedures by Type, U.S., 2020 – 2030 (2 of 2) |
| Figure 6‑40: Orthopedic Cartilage Repair Procedures by Patient Type, U.S., 2020 – 2030 |
| Figure 6‑41: Orthopedic Cartilage Repair Procedures by Care Setting, U.S., 2020 – 2030 |
| Figure 7‑1: Orthopedic Bone Graft Substitute Units per Procedure by Indication, U.S., 2020 – 2030 |
| Figure 7‑2: Orthopedic Bone Graft Substitute Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 7‑3: Orthopedic Bone Graft Substitute Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 7‑4: Orthopedic Bone Graft Substitute Market, U.S., 2020 – 2030 |
| Figure 7‑5: Allograft Bone Graft Substitute Market, U.S., 2020 – 2030 |
| Figure 7‑6: Xenograft Bone Graft Substitute Market, U.S., 2020 – 2030 |
| Figure 7‑7: Demineralized Bone Matrix Allograft Bone Graft Substitute Market, U.S., 2020 – 2030 |
| Figure 7‑8: Synthetic Bone Graft Substitute Market, U.S., 2020 – 2030 |
| Figure 7‑9: Synthetic Bone Graft Substitute Market by Generation Type, U.S., 2020 – 2030 (US$M) |
| Figure 7‑10: Generation 1 Synthetic Bone Graft Substitute Market, U.S., 2020 – 2030 |
| Figure 7‑11: Generation 2 Synthetic Bone Graft Substitute Market, U.S., 2020 – 2030 |
| Figure 7‑12: Allograft Bone Graft Substitute Units Sold by Indication, U.S., 2020 – 2030 |
| Figure 7‑13: Spine Allograft Bone Graft Substitute Units Sold, U.S., 2020 – 2030 |
| Figure 7‑14: Spine Allograft Bone Graft Substitute Units Sold by Product Type, U.S., 2020 – 2030 |
| Figure 7‑15: Trauma Allograft Bone Graft Substitute Units Sold, U.S., 2020 – 2030 |
| Figure 7‑16: Large Joint Reconstruction Allograft Bone Graft Substitute Units Sold, U.S., 2020 – 2030 |
| Figure 7‑17: Allograft Bone Graft Substitute Units Sold by Patient Type, U.S., 2020 – 2030 |
| Figure 7‑18: Allograft Bone Graft Substitute Units Sold by Setting Type, U.S., 2020 – 2030 |
| Figure 7‑19: Allograft Bone Graft Substitute Units Sold by Product Type, U.S., 2020 – 2030 (1 of 2) |
| Figure 7‑20: Allograft Bone Graft Substitute Units Sold by Product Type, U.S., 2020 – 2030 (2 of 2) |
| Figure 7‑21: Xenograft Bone Graft Substitute Units Sold by Indication, U.S., 2020 – 2030 |
| Figure 7‑22: Spine Xenograft Bone Graft Substitute Units Sold, U.S., 2020 – 2030 |
| Figure 7‑23: Spine Xenograft Bone Graft Substitute Units Sold by Product Type, U.S., 2020 – 2030 |
| Figure 7‑24: Trauma Xenograft Bone Graft Substitute Units Sold, U.S., 2020 – 2030 |
| Figure 7‑25: Large Joint Reconstruction Xenograft Bone Graft Substitute Units Sold, U.S., 2020 – 2030 |
| Figure 7‑26: Xenograft Bone Graft Substitute Units Sold by Patient Type, U.S., 2020 – 2030 |
| Figure 7‑27: Xenograft Bone Graft Substitute Units Sold by Setting Type, U.S., 2020 – 2030 |
| Figure 7‑28: Xenograft Bone Graft Substitute Units Sold by Product Type, U.S., 2020 – 2030 |
| Figure 7‑29: DBM with Carriers Market, U.S., 2020-2030 |
| Figure 7‑30: DBM without Carriers Market, U.S., 2020-2030 |
| Figure 7‑31: Demineralized Bone Matrix Allograft Bone Graft Substitute Units Sold by Indication, U.S., 2020 – 2030 |
| Figure 7‑32: Spine Demineralized Bone Matrix Allograft Bone Graft Substitute Units Sold, U.S., 2020 – 2030 |
| Figure 7‑33: Spine Demineralized Bone Matrix Bone Graft Substitute Units Sold by Product Type, U.S., 2020 – 2030 |
| Figure 7‑34: Trauma Demineralized Bone Matrix Allograft Bone Graft Substitute Units Sold, U.S., 2020 – 2030 |
| Figure 7‑35: Large Joint Reconstruction Demineralized Bone Matrix Allograft Bone Graft Substitute Units Sold, U.S., 2020 – 2030 |
| Figure 7‑36: Demineralized Bone Matrix Allograft Bone Graft Substitute Units Sold by Patient Type, U.S., 2020 – 2030 |
| Figure 7‑37: Demineralized Bone Matrix Allograft Bone Graft Substitute Units Sold by Setting Type, U.S., 2020 – 2030 |
| Figure 7‑38: Demineralized Bone Matrix Bone Graft Substitute Units Sold by Product Type, U.S., 2020 – 2030 (1 of 2) |
| Figure 7‑39: Demineralized Bone Matrix Bone Graft Substitute Units Sold by Product Type, U.S., 2020 – 2030 (2 of 2) |
| Figure 7‑40: Synthetic Bone Graft Substitute Units Sold by Indication, U.S., 2020 – 2030 |
| Figure 7‑41: Spine Synthetic Bone Graft Substitute Units Sold, U.S., 2020 – 2030 |
| Figure 7‑42: Spine Synthetic Bone Graft Substitute Units Sold by Product Type, U.S., 2020 – 2030 |
| Figure 7‑43: Trauma Synthetic Bone Graft Substitute Units Sold, U.S., 2020 – 2030 |
| Figure 7‑44: Large Joint Reconstruction Synthetic Bone Graft Substitute Units Sold, U.S., 2020 – 2030 |
| Figure 7‑45: Synthetic Bone Graft Substitute Units Sold by Patient Type, U.S., 2020 – 2030 |
| Figure 7‑46: Synthetic Bone Graft Substitute Units Sold by Setting Type, U.S., 2020 – 2030 |
| Figure 7‑47: Synthetic Bone Graft Substitute Units Sold by Patient Type, U.S., 2020 – 2030 |
| Figure 7‑48: Synthetic Bone Graft Substitute Units Sold by Product Type, U.S., 2020 – 2030 (1 of 2) |
| Figure 7‑49: Synthetic Bone Graft Substitute Units Sold by Product Type, U.S., 2020 – 2030 (2 of 2) |
| Figure 7‑50: Leading Competitors, Orthopedic Bone Graft Substitute Market, U.S., 2023 |
| Figure 8‑1: Orthopedic Growth Factor Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 8‑2: Orthopedic Growth Factor Market, U.S., 2020 – 2030 |
| Figure 8‑3: Cervical Disc Degeneration Orthopedic Growth Factor Market, U.S., 2020 – 2030 |
| Figure 8‑4: Tibial Fracture Orthopedic Growth Factor Market, U.S., 2020 – 2030 |
| Figure 8‑5: Spine Orthopedic Growth Factor Market, U.S., 2020 – 2030 |
| Figure 8‑6: Ankle & Hindfoot Fusion Orthopedic Growth Factor Market, U.S., 2020 – 2030 |
| Figure 8‑7: Cervical Disc Degeneration Growth Factor Units Sold by Setting Type, U.S., 2020 – 2030 |
| Figure 8‑8: Tibial Fracture Growth Factor Units Sold by Setting Type, U.S., 2020 – 2030 |
| Figure 8‑9: Spine Growth Factor Units Sold by Setting Type, U.S., 2020 – 2030 |
| Figure 8‑10: Ankle and Hindfoot Fusion Growth Factor Units Sold by Setting Type, U.S., 2020 – 2030 |
| Figure 8‑11: Leading Competitors, Orthopedic Growth Factor Market, U.S., 2023 |
| Figure 9‑1: Orthopedic Cellular Allograft Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 9‑2: Orthopedic Cellular Allograft Market, U.S., 2020 – 2030 |
| Figure 9‑3: Cervical Spine Orthopedic Cellular Allograft Market, U.S., 2020 – 2030 |
| Figure 9‑4: Lumbar Spine Orthopedic Cellular Allograft Market, U.S., 2020 – 2030 |
| Figure 9‑5: Foot and Ankle Cellular Allograft Market, U.S., 2020 – 2030 |
| Figure 9‑6: Trauma Cellular Allograft Market, U.S., 2020 – 2030 |
| Figure 9‑7: Leading Competitors, Orthopedic Cellular Allograft Market, U.S., 2023 |
| Figure 10‑1: Orthopedic Cell Therapy Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 10‑2: Platelet-Rich Plasma Market, U.S., 2020 – 2030 |
| Figure 10‑3: Bone Marrow Aspirate Concentrate Market, U.S., 2020 – 2030 |
| Figure 10‑4: Platelet-Rich Plasma Units Sold by Indication Anatomy, U.S., 2020 – 2030 |
| Figure 10‑5: Bone Marrow Aspirate Concentrate Units Sold by Indication Anatomy, U.S., 2020 – 2030 |
| Figure 10‑6: Leading Competitors, Orthopedic Cell Therapy Market, U.S., 2023 |
| Figure 11‑1: Hyaluronic Acid Viscosupplementation Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 11‑2: Hyaluronic Acid Viscosupplementation Market, U.S., 2020 – 2030 |
| Figure 11‑3: Single-Injection Hyaluronic Acid Viscosupplementation Market, U.S., 2020 – 2030 |
| Figure 11‑4: Two-Injection Hyaluronic Acid Viscosupplementation Market, U.S., 2020 – 2030 |
| Figure 11‑5: Three-Injection Hyaluronic Acid Viscosupplementation Market, U.S., 2020 – 2030 |
| Figure 11‑6: Five-Injection Hyaluronic Acid Viscosupplementation Market, U.S., 2020 – 2030 |
| Figure 11‑7: Leading Competitors, Hyaluronic Acid Viscosupplementation Market, U.S., 2023 |
| Figure 12‑1: Orthopedic Cartilage Repair Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 12‑2: Osteochondral Allograft Market, U.S., 2020 – 2030 |
| Figure 12‑3: Meniscal Allograft Market, U.S., 2020 – 2030 |
| Figure 12‑4: Autologous Chondrocyte Implantation Market, U.S., 2020 – 2030 |
| Figure 12‑5: Particulated Juvenile Allograft Market, U.S., 2020 – 2030 |
| Figure 12‑6: Microfracture Adjunct Market, U.S., 2020 – 2030 |
| Figure 12‑7: Osteochondral Allograft Cartilage Repair Units Sold by Patient Type, U.S., 2020 – 2030 |
| Figure 12‑8: Meniscal Allograft Cartilage Repair Units Sold by Patient Type, U.S., 2020 – 2030 |
| Figure 12‑9: Autologous Chondrocyte Implantation Cartilage Repair Units Sold by Patient Type, U.S., 2020 – 2030 |
| Figure 12‑10: Particulated Juvenile Cartilage Repair Units Sold by Patient Type, U.S., 2020 – 2030 |
| Figure 12‑11: Microfracture Adjunct Cartilage Repair Units Sold by Patient Type, U.S., 2020 – 2030 |
| Figure 12‑12: Leading Competitors, Orthopedic Cartilage Repair Market, U.S., 2023 |
